Polycystic ovary syndrome affects a striking 9-18% of Australian reproductive aged women and
has been associated with a number of metabolic abnormalities.
Given the strong correlation between metabolic abnormalities and increased sympathetic
activity, we hypothesise that reducing this activity using medication (moxonidine) can help
improve the metabolic abnormalities, and therefore improve outcomes in polycystic ovary
syndrome.
Phase:
Phase 4
Details
Lead Sponsor:
Baker Heart and Diabetes Institute Baker IDI Heart and Diabetes Institute